DNL593 + Placebo
Phase 1/2Active 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Frontotemporal Dementia
Conditions
Frontotemporal Dementia
Trial Timeline
Feb 1, 2022 → Nov 1, 2028
NCT ID
NCT05262023About DNL593 + Placebo
DNL593 + Placebo is a phase 1/2 stage product being developed by Denali Therapeutics for Frontotemporal Dementia. The current trial status is active. This product is registered under clinical trial identifier NCT05262023. Target conditions include Frontotemporal Dementia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05262023 | Phase 1/2 | Active |
Competing Products
7 competing products in Frontotemporal Dementia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo + Open label - AL001 | Alector | Phase 3 | 69 |
| AL001 | Alector | Phase 2 | 44 |
| LY3884963 + Methylprednisolone + Optional Sirolimus + Optional Prednisone | Eli Lilly | Phase 1/2 | 41 |
| galantamine hydrobromide | Johnson & Johnson | Phase 2 | 52 |
| memantine hydrochloride | Lundbeck | Phase 3 | 74 |
| Syntocinon | Brain Biotech | Phase 2 | 44 |
| PBFT02 | Passage Bio | Phase 1/2 | 33 |